Endobotics v. Hologic: Surgical Sealing Patent Dispute Settled in 200 Days
Endobotics, LLC filed suit against medical device giant Hologic, Inc. in Massachusetts federal court, asserting three patents covering surgical vessel-sealing technology against Hologic’s CoolSeal Portfolio, CoolSeal Mini, CoolSeal Reveal, CoolSeal Trinity, and JustRight product lines. The parties reached a settlement in just 200 days — a notably swift resolution for multi-patent medical device litigation.
A fast-tracked surgical device IP dispute ends at the negotiating table
On March 22, 2024, Endobotics, LLC filed a patent infringement action against Hologic, Inc. in the U.S. District Court for the District of Massachusetts before Judge Patti B. Saris. The complaint asserted three patents — US7364582B2, US7338513B2, and US7147650B2 — covering surgical vessel-sealing device technology. The accused products span Hologic’s CoolSeal Portfolio (including the CoolSeal Trinity, CoolSeal Mini, and CoolSeal Reveal) and the JustRight line, suggesting broad commercial exposure across Hologic’s minimally invasive surgery offerings.
On September 20, 2024, the court was advised that the action had been settled. Judge Saris issued an order dismissing the case without prejudice, preserving both parties’ right to reopen within 60 days should the settlement not be consummated. The without-prejudice dismissal is standard practice for settlement holds, but it also means the patents remain unchallenged on the merits — Hologic did not secure any invalidity finding, and Endobotics retains full enforceability of all three asserted patents.
The 200-day resolution is notably compressed for litigation involving three patents and multiple accused product lines from a publicly traded medical device company. This pace suggests either pre-suit licensing discussions that matured quickly, or a business calculus at Hologic that early settlement was preferable to protracted litigation risk. The financial terms and any licensing arrangements remain confidential, leaving the market to infer strategic motivations. What is clear from the public record is that Endobotics demonstrated credible enforcement capability with a well-resourced law firm and counsel on both sides.
Filing to Case Settled in 200 days
200-day resolution — faster than the median multi-patent district court case, which typically exceeds 2 years
Case settled: what the without-prejudice dismissal means for both parties
Without-prejudice dismissal preserves optionality on both sides
A settlement-based dismissal without prejudice means neither party obtained a merits ruling. The court’s 60-day reopening window is a procedural safeguard — if the settlement agreement falls apart before execution, either party can petition to reinstate the case. Once the window lapses without reopening, the dismissal becomes effectively final, though the underlying patents remain fully valid and enforceable.
No merits adjudicationEndobotics exits with patents intact and confidential terms
Endobotics achieved settlement in under seven months without any validity challenge proceeding to judgment. All three asserted patents — US7364582B2, US7338513B2, and US7147650B2 — survive the litigation with enforceability unimpaired. Whether Endobotics secured a licensing royalty, lump-sum payment, or product design-around agreement is not disclosed in the public record, but the swift outcome is consistent with a plaintiff that held credible, commercially relevant IP.
Patents remain enforceableHologic avoids merits ruling but gains no invalidity protection
Hologic, represented by Arnold & Porter Kaye Scholer, secured closure without a public damages award or injunction, protecting its CoolSeal and JustRight product lines in the near term. However, the company did not obtain an invalidity or non-infringement finding. This means Hologic — and potentially other manufacturers using similar sealing technology — remain exposed to these patents in future enforcement actions if licensing terms are not sustained.
No invalidity finding securedSurgical sealing device sector faces unresolved patent risk
The settlement leaves three surgical vessel-sealing patents standing unchallenged, signalling that competitors in the minimally invasive surgery space — particularly makers of energy-based sealing and cutting instruments — should treat these patents as active enforcement risk. Endobotics has now demonstrated a willingness and capability to assert this portfolio against a major commercial player, which typically signals broader licensing or enforcement activity in the sector.
Active enforcement risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Endobotics, LLC | Company | Medical device IP holding company — holder of US7364582B2, US7338513B2, and US7147650B2Search in Eureka ↗ |
| Defendant | Hologic, Inc. | Company | Hologic, Inc. — publicly traded medical device company; maker of CoolSeal and JustRight surgical platformsSearch in Eureka ↗ |
| Plaintiff counsel | Ariel Reinitz | Attorney | Counsel for Endobotics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Scott H. Bernstein | Attorney | Counsel for Endobotics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Bochner PLLC | Law Firm | Representing Endobotics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Law Offices Of Scott H. Bernstein, LLC | Law Firm | Representing Endobotics, LLCSearch in Eureka ↗ |
| Defendant counsel | Drew Needham | Attorney | Counsel for Hologic, Inc.Search in Eureka ↗ |
| Defendant counsel | Jennifer Sklenar | Attorney | Counsel for Hologic, Inc.Search in Eureka ↗ |
| Defendant counsel | Joshua S. Barlow | Attorney | Counsel for Hologic, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew M. Wolf | Attorney | Counsel for Hologic, Inc.Search in Eureka ↗ |
| Defendant counsel | Wallace Wu | Attorney | Counsel for Hologic, Inc.Search in Eureka ↗ |
| Defendant law firm | Arnold & Porter Kaye Scholer LLP | Law Firm | Representing Hologic, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Patti B. Saris | Judge | Massachusetts District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a standard settlement-hold dismissal under local practice: the action is dismissed without prejudice, preserving a 60-day window to reopen if the settlement is not consummated. The phrasing ‘good cause shown’ sets a threshold for reinstatement. Critically, the order contains no merits findings — no claim construction, no validity ruling, and no infringement determination — meaning the three asserted patents retain full presumptive validity and enforceability following this disposition.
US7364582B2, US7338513B2 & US7147650B2 — Surgical Vessel-Sealing Devices
The three asserted patents — US7364582B2, US7338513B2, and US7147650B2 — originate from U.S. applications filed in the mid-2000s (application nos. 11/429796, 11/302654, and 10/822081 respectively), covering electrosurgical vessel-sealing instrument designs. These patents protect core aspects of how surgical tools grip, seal, and divide tissue and blood vessels during minimally invasive procedures — a functionality central to laparoscopic and robotic-assisted surgery platforms.
Vessel-sealing patents of this vintage carry significant commercial weight because they cover foundational design architectures that underpin a wide range of modern energy-based surgical instruments. Hologic’s CoolSeal and JustRight product lines are precisely the type of commercial embodiments that such claims are designed to capture. For competitors developing or acquiring surgical instrument platforms, the survival of these patents without challenge means the enforceability risk profile has not diminished — and Endobotics has now signalled its willingness to litigate in federal court.
Should you run an FTO against US7364582B2, US7338513B2 & US7147650B2?
Any company designing, manufacturing, or commercialising energy-based vessel-sealing instruments — particularly those with jaw-based tissue-gripping and electrosurgical cutting functionality — should conduct a freedom-to-operate analysis against all three Endobotics patents. The claims survived litigation against Hologic, a major OEM, without any invalidity ruling. Product teams launching or iterating on laparoscopic sealing devices are squarely in scope.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US7364582B2, US7338513B2, and US7147650B2 against your product specifications, identify related continuation and divisional filings in the Endobotics portfolio, and surface design-around prior art — all in a fraction of the time of manual prosecution history review. Start with a portfolio-level landscape to understand enforcement perimeter before product launch.
Run a freedom-to-operate analysis on US7364582B2 to assess your product’s exposure
Run FTO in Eureka →Similar surgical device patent infringement cases in U.S. district courts
Explore related patent infringement cases involving electrosurgical and vessel-sealing device technology litigated in U.S. district courts, including Massachusetts.
What this case signals for the surgical device IP landscape
A swift settlement against a major medical device OEM suggests Endobotics holds commercially potent IP — and knows how to deploy it.
Three unchallenged patents signal a live enforcement portfolio
No IPR petition or invalidity counterclaim reached judgment. All three Endobotics patents emerge from this litigation with enforceability intact. Any company selling energy-based vessel-sealing devices should treat US7364582B2, US7338513B2, and US7147650B2 as active FTO risks — particularly those with products functionally similar to Hologic’s CoolSeal or JustRight platforms.
200-day resolution is atypical — and strategically informative
Multi-patent medical device cases rarely settle before claim construction. The speed here suggests either pre-existing licensing discussions, high settlement pressure from Hologic’s product revenue exposure, or both. For IP strategists, this pattern is consistent with a plaintiff that had strong claim charts and a defendant weighing litigation cost against commercial continuity.
Endobotics v Hologic — key questions answered
Endobotics asserted three patents: US7364582B2, US7338513B2, and US7147650B2. All three cover surgical vessel-sealing instrument technology. The accused Hologic products included the CoolSeal Portfolio (Trinity, Mini, Reveal) and the JustRight line. No invalidity or non-infringement ruling was issued; the case settled in September 2024.
The case was settled on September 20, 2024, and dismissed without prejudice by Judge Patti B. Saris. ‘Without prejudice’ means either party could petition to reopen within 60 days if the settlement was not finalised. Once that window lapses, the dismissal is effectively permanent. No financial terms or licensing arrangements were disclosed in the public record.
No. The case settled before any claim construction or merits ruling. Hologic did not obtain an invalidity or non-infringement determination. All three asserted patents — US7364582B2, US7338513B2, and US7147650B2 — retain full presumptive validity and remain enforceable against third parties in subsequent actions.
The 200-day resolution is atypically fast for multi-patent medical device litigation, which often exceeds two years. The speed suggests pre-existing licensing discussions, strong claim charts that reduced Hologic’s confidence in an invalidity defence, or a commercial decision by Hologic to avoid litigation disruption to its CoolSeal and JustRight product revenue. The precise drivers are not disclosed in the public record.
The complaint accused Hologic’s CoolSeal Portfolio — including the CoolSeal Trinity (model nos. CSL-TR105-30, CSL-TR105-37, CSL-TR105-44), CoolSeal Mini (model no. CSL-MN103-10), and CoolSeal Reveal (model no. CSL-RV105-10) — as well as the JustRight product (model no. JR-ST25-2.0-6). These are commercially active electrosurgical sealing and cutting instruments used in minimally invasive surgery.
PatSnap Eureka searches patents and litigation data to answer instantly.